116 related articles for article (PubMed ID: 23602204)
1. Retrospective monitoring of minimal residual disease using hairpin-shaped clone specific primers in B-cell lymphoma affected dogs.
Gentilini F; Turba ME; Forni M
Vet Immunol Immunopathol; 2013 Jun; 153(3-4):279-88. PubMed ID: 23602204
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
[TBL] [Abstract][Full Text] [Related]
3. Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.
Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2011; 25(2):292-6. PubMed ID: 21314721
[TBL] [Abstract][Full Text] [Related]
4. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: a proof-of-concept pilot study.
Yamazaki J; Takahashi M; Setoguchi A; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2010; 24(4):897-903. PubMed ID: 20492493
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma.
Sato M; Yamzaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2013 Mar; 195(3):319-24. PubMed ID: 22909955
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.
Aresu L; Aricò A; Ferraresso S; Martini V; Comazzi S; Riondato F; Giantin M; Dacasto M; Guadagnin E; Frayssinet P; Rouquet N; Drigo M; Marconato L
Vet J; 2014 May; 200(2):318-24. PubMed ID: 24698669
[TBL] [Abstract][Full Text] [Related]
8. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission.
Sato M; Yamazaki J; Goto-Koshino Y; Setoguchi A; Takahashi M; Baba K; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2016 Sep; 215():38-42. PubMed ID: 27339366
[TBL] [Abstract][Full Text] [Related]
10. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.
Miglino M; Santini G; Grasso R; Pietrasanta D; Clavio M; Pierri I; Canepa L; Nati S; Ballerini F; Varaldo R; Palmisano G; Gobbi M
Haematologica; 2001 Jul; 86(7):706-14. PubMed ID: 11454525
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
14. Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.
Cikota BM; Tukić LJ; Tarabar OT; Magić ZM
J Exp Clin Cancer Res; 2007 Dec; 26(4):535-42. PubMed ID: 18365550
[TBL] [Abstract][Full Text] [Related]
15. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
16. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
[TBL] [Abstract][Full Text] [Related]
17. Real-time quantitative PCR using hairpin-shaped clone-specific primers for minimal residual disease assessment in an animal model of human non-Hodgkin lymphoma.
Gentilini F; Turba ME; Calzolari C; Cinotti S; Forni M; Zannoni A
Mol Cell Probes; 2010 Feb; 24(1):6-14. PubMed ID: 19651205
[TBL] [Abstract][Full Text] [Related]
18. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
19. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
20. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
